Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease

Trial Profile

Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs TAK 214 (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors LigoCyte Pharmaceuticals
  • Most Recent Events

    • 12 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2014 Results presented at the 16th International Congress on Infectious Diseases.
    • 04 Oct 2013 Results will be presented at IDWeek 2013 according to a Takeda Pharmaceuticals media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top